This report critically examines the promotional claim that oral L-arginine supplementation, marketed in formulas such as Omnilife's "Power Maker," induces a sustained increase in height of approximately 1.5 centimeters per month in adults through the release of growth hormone (GH). Based on available evidence in endocrinology, pharmacokinetics, bone development biology, virology, and pharmacovigilance, this claim is shown to be biochemically, physiologically, and biomechanically unsustainable. The analysis establishes that: (i) commercial doses of 3 g are subtherapeutic compared to the 6–30 g used as a diagnostic test of somatotrophic reserve; (ii) the transient GH peak induced by L-arginine does not result in clinically relevant increases in hepatic IGF-1 and is attenuated or even suppressed when combined with exercise; (iii) Longitudinal elongation of the adult skeleton is physically impossible after epiphyseal fusion, mediated by estrogens and consolidated around 16–19 years of age; and (iv) chronic free arginine overload carries documented risks—gastrointestinal disorders, HSV reactivation, trabecular deterioration in osteoporosis models, and, with sustained supraphysiological exposure, acromegalic and cardiovascular risk. It is concluded that the marketing claim constitutes a regulatoryly relevant deception, unsupported by peer-reviewed biomedical literature. Keywords: L-arginine; growth hormone; IGF-1; epiphyseal fusion; dietary supplements; pharmacovigilance; deceptive advertising.